Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 2BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
Calcium folinate pentahydrate
Mayo Clinic
Phase 2BB
METHOTREXATE
Mayo Clinic
Phase 2BB
Cytosin-Arabinosid
Mayo Clinic
Phase 2BB

View all 24 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →